Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.66 |
| ▸ | PPARA | Q07869 | 20/20 | 0.66 |
| ▸ | PPARD | Q03181 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3743468 | 0.92 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL7620874 | 0.91 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3745188 | 0.91 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL3730093 | 0.90 | PPARG (0.56) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL29365673 | 0.90 | PPARG (0.64) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL2642937 | 0.90 | PPARG (0.64) | PPARGPPARAPPARD | |
| Edaglitazone SCHEMBL22607966 | 0.89 | PPARG (0.64) | PPARGPPARAPPARD | |
| SCHEMBL13524846 | 0.87 | PPARG (0.55) | PPARGPPARAPPARD | |
| SCHEMBL7626097 | 0.86 | PPARG (0.54) | PPARGPPARAPPARD | |
| SCHEMBL2643279 | 0.86 | PPARG (0.51) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176787-A1 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-11 | — | — | US | claimed |
| US-7323481-B2 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | HOFFMANN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20050176787-A1 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-11 | — | — | US | disclosed |
| EP-1392296-A1 | THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002080913-A1 | THIAZOLIDINEDIONES ALONE OR IN COMBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176787-A1 | Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth | PPARD, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.